Literature DB >> 17192038

Detection of a K-ras mutation in urine of patients with colorectal cancer.

Ying-Hsiu Su1, Mengjun Wang, Benjamas Aiamkitsumrit, Dean E Brenner, Timothy M Block.   

Abstract

We previously demonstrated that human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation, which may be useful in the detection of colorectal cancer. In this report we have determined the stability of DNA in urine and have found that the half-life time interval of this small, fragmented DNA is at least 4 hours post collection. We further compared, in a blinded study, the frequency of detecting mutated K-ras sequence in DNA isolated from plasma and urine derived from individuals who have either a colorectal carcinoma (CRC), or adenomatous polyps that contain a mutation in codon 12 of the K-ras proto-oncogene. There was an 83% concurrence of mutated DNA detected in urine and its corresponding disease tissue from the same individuals, when paired urine and tissue sections from 20 patients with either CRC or adenomatous polyps were analyzed for K-ras mutation. However, only a 56% concurrence was observed when the matched plasma specimens were tested from these 20 patients. These results suggest that urine might be a better resource for detecting K-ras mutation in circulating DNA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 17192038     DOI: 10.3233/cbm-2005-12-305

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  18 in total

Review 1.  Molecular screening of cancer: the future is here.

Authors:  Sudhir Srivastava
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

Review 2.  Urine test for EGFR analysis in patients with non-small cell lung cancer.

Authors:  Aleksandra Franovic; Victoria M Raymond; Mark G Erlander; Karen L Reckamp
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

3.  Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma.

Authors:  Hiroyuki Terasawa; Hideaki Kinugasa; Soichiro Ako; Mami Hirai; Hiroshi Matsushita; Daisuke Uchida; Takeshi Tomoda; Kazuyuki Matsumoto; Shigeru Horiguchi; Hironari Kato; Kazuhiro Nouso; Hiroyuki Okada
Journal:  Cancer Biol Ther       Date:  2019-07-22       Impact factor: 4.742

4.  A locked nucleic acid clamp-mediated PCR assay for detection of a p53 codon 249 hotspot mutation in urine.

Authors:  Selena Y Lin; Veerpal Dhillon; Surbhi Jain; Ting-Tsung Chang; Chi-Tan Hu; Yih-Jyh Lin; Shun-Hua Chen; Kung-Chao Chang; Wei Song; Lixin Yu; Timothy M Block; Ying-Hsiu Su
Journal:  J Mol Diagn       Date:  2011-07-02       Impact factor: 5.568

5.  Differential methylation of the promoter and first exon of the RASSF1A gene in hepatocarcinogenesis.

Authors:  Surbhi Jain; Lijia Xie; Batbold Boldbaatar; Selena Y Lin; James P Hamilton; Stephen J Meltzer; Shun-Hua Chen; Chi-Tan Hu; Timothy M Block; Wei Song; Ying-Hsiu Su
Journal:  Hepatol Res       Date:  2014-12-09       Impact factor: 4.288

Review 6.  Urine-Based Liquid Biopsy for Nonurological Cancers.

Authors:  Surbhi Jain; Selena Y Lin; Wei Song; Ying-Hsiu Su
Journal:  Genet Test Mol Biomarkers       Date:  2019-04

7.  Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma.

Authors:  Hie-Won Hann; Surbhi Jain; Grace Park; Jamin D Steffen; Wei Song; Ying-Hsiu Su
Journal:  Hepatoma Res       Date:  2017-06-06

Review 8.  Clinical applications of urinary cell-free DNA in cancer: current insights and promising future.

Authors:  Tian Lu; Jinming Li
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

Review 9.  Colorectal cancer: from prevention to personalized medicine.

Authors:  Gemma Binefa; Francisco Rodríguez-Moranta; Alex Teule; Manuel Medina-Hayas
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

10.  High-fidelity DNA polymerase enhances the sensitivity of a peptide nucleic acid clamp PCR assay for K-ras mutations.

Authors:  Bjørnar Gilje; Reino Heikkilä; Satu Oltedal; Kjersti Tjensvoll; Oddmund Nordgård
Journal:  J Mol Diagn       Date:  2008-06-13       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.